Dr. Reddy's Q1 FY27: Semaglutide Charge Obscures Strong Base Business
RDY is trading near its 52-week low of $12.185 (0.0% above the low).
Summary
A ₹190 Cr semaglutide API charge hit Dr. Reddy's Q1 FY27 reported profits, but the underlying base business grew double digits across all regions with a 15.4% EBITDA margin ex-impact.
Key Events · Earnings and Guidance · RDY
-
Semaglutide API Charge Hits Q1
A ₹190 Cr charge for semaglutide API inventory provision and associated costs dragged the reported EBITDA margin to 12.5%, down from 15.4% ex-impact.
-
Base Business Delivers Double-Digit Growth
Excluding the semaglutide impact, revenues grew across all segments: North America +35% YoY, India +17%, Emerging Markets +31%, and Europe +13%.
-
Strong Balance Sheet
As of June 30, 2026, a net cash surplus of ₹5,027 Cr provides ample liquidity to navigate the semaglutide supply disruption.
-
Regulatory Overhang Persists
A Form 483 with 7 observations was received at the biologics facility in June 2026; the company has responded within the timeline.
Analysis · RDY · Life Sciences
A ₹190 Cr semaglutide API charge dragged Dr. Reddy's reported Q1 FY27 EBITDA margin to 12.5%, but stripping out that one-time hit reveals a healthy 15.4% margin on double-digit revenue growth across all geographies. The previously flagged quality issue has now materialized financially, yet the underlying generics engine is performing well—North America grew 35% YoY, India 17%, and Emerging Markets 31%. The company maintains a strong net cash position of ₹5,027 Cr. The market will need to weigh the temporary semaglutide setback against the broad-based operational strength.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $12.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $12.19 to $15.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.